Regulatory landscape The regulatory situation for compounded tirzepatide has shifted significantly
The researchers found this reassuring since it showed that participants were taking the medication as prescribed and validated the heart metrics recorded
2025;48(Suppl 1):S12845
FDA investigating counterfeit weight loss drugs, trade group says One provider meant to dose 0.25 milligrams, or 5 units, but prescribed 25 units instead, leading to a patient getting five times the intended dose and experiencing severe vomiting, the FDA relayed
They are not FDA-approved drugs, but they are legally prescribed as compounded medications under physician supervision
Savvidou S, Karatzidou K, Tsakiri K, Gagalis A, Hytiroglou P, Goulis J